Rhenman & Partners Asset Management AB reduced its holdings in Epizyme Inc (NASDAQ:EPZM) by 8.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 450,028 shares of the biopharmaceutical company’s stock after selling 43,651 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Epizyme were worth $4,642,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of EPZM. Marshall Wace North America L.P. bought a new position in Epizyme in the 1st quarter worth approximately $235,000. Metropolitan Life Insurance Co NY increased its position in Epizyme by 18.3% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 3,029 shares during the period. FMR LLC increased its position in Epizyme by 0.3% in the 1st quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock worth $43,169,000 after buying an additional 11,759 shares during the period. Strs Ohio increased its position in Epizyme by 135.7% in the 2nd quarter. Strs Ohio now owns 30,614 shares of the biopharmaceutical company’s stock worth $384,000 after buying an additional 17,623 shares during the period. Finally, Quantitative Systematic Strategies LLC bought a new position in Epizyme in the 2nd quarter worth approximately $188,000. 86.30% of the stock is currently owned by institutional investors.
Several research analysts have commented on the company. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating and set a $15.00 price target on the stock. in a research report on Wednesday, August 14th. ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. BidaskClub downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Tuesday, September 24th. Finally, HC Wainwright set a $25.00 price target on Epizyme and gave the stock a “buy” rating in a research report on Monday, June 24th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Epizyme has an average rating of “Hold” and an average target price of $17.25.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). The firm had revenue of $5.90 million during the quarter, compared to analyst estimates of $0.32 million. The company’s revenue for the quarter was down 50.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.42) EPS. As a group, equities research analysts forecast that Epizyme Inc will post -2.2 earnings per share for the current fiscal year.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: Lock-Up Period Expiration
Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.